Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP8 | P22894 | 1/20 | 0.40 |
| ▸ | ACACB | O00763 | 1/20 | 0.36 |
| ▸ | ACACA | Q13085 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.34 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.33 |
| ▸ | MGAM | O43451 | 1/20 | 0.33 |
| ▸ | SI | P14410 | 1/20 | 0.33 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.33 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14593938 | 0.84 | MMP8 (0.47) | MMP8ALDH1A1CYP2C19CYP3A4GAA | |
| SCHEMBL16438140 | 0.82 | ACACB (0.39) | ACACBACACACYP1A2CYP2C9 | |
| SCHEMBL17278939 | 0.82 | ACACB (0.37) | MMP8ACACBACACAALDH1A1CYP2C19 | |
| SCHEMBL28291065 | 0.81 | MMP8 (0.43) | MMP8ALDH1A1CYP2C19CYP3A4GAA | |
| SCHEMBL12598259 | 0.81 | MMP8 (0.45) | MMP8ALDH1A1CYP2C19CYP3A4GAA | |
| Dimebutic Acid SCHEMBL30499226 | 0.81 | ACACB (0.34) | MMP8ACACBACACAALDH1A1CYP2C19 | |
| SCHEMBL13252739 | 0.81 | MMP8 (0.38) | MMP8ALDH1A1CYP2C19CYP3A4GAA | |
| SCHEMBL18886818 | 0.80 | ACACB (0.36) | ACACBACACA | |
| SCHEMBL18886824 | 0.80 | ACACB (0.36) | ACACBACACA | |
| SCHEMBL14307176 | 0.78 | ACACB (0.35) | ACACBACACAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2288589-B1 | FRUITY ODORANT | FIRMENICH & CIE (CH) | 2013-01-02 | — | — | EP | claimed |
| US-20230346733-A1 | ORAL FORMULATIONS OF BIPOLAR TRANS CAROTENOIDS | DIFFUSION PHARMACEUTICALS LLC (US) | 2023-11-02 | — | — | US | disclosed |
| US-20230301923-A1 | MUCO-ADHESIVE, CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOF | IMPAX LABORATORIES, LLC (US) | 2023-09-28 | — | — | US | disclosed |
| US-11666538-B2 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof | IMPAX LABORATORIES, LLC (US) | 2023-06-06 | — | — | US | disclosed |
| US-10016384-B2 | Oral formulations of bipolar trans carotenoids | DIFFUSION PHARMACEUTICALS LLC (US) | 2018-07-10 | — | — | US | disclosed |
| US-20180000903-A1 | Tablets Comprising GLP-1 Agonist and Enteric Coating | NOVO NORDISK A/S (DK) | 2018-01-04 | — | — | US | disclosed |
| US-20160354315-A1 | DOSAGE FORMS AND USE THEREOF | Triastek, Inc. (CN) | 2016-12-08 | — | — | US | disclosed |
| US-20160354315-A1 | DOSAGE FORMS AND USE THEREOF | Triastek, Inc. (CN) | 2016-12-08 | — | — | US | disclosed |
| US-20160296427-A1 | SYSTEM AND METHOD FOR APPLYING ORAL CARE AGENTS | KONINKLIJKE PHILIPS N.V. (NL) | 2016-10-13 | — | — | US | disclosed |
| US-20160296427-A1 | SYSTEM AND METHOD FOR APPLYING ORAL CARE AGENTS | KONINKLIJKE PHILIPS N.V. (NL) | 2016-10-13 | — | — | US | disclosed |
| US-20100189790-A1 | Delayed release rasagiline formulation | TEVA PHARMACEUTICAL INDUSTRIES, LTD. | 2010-07-29 | — | — | US | disclosed |
| US-20100190859-A1 | Monorasagiline citrate; salt formation; monoamine oxidase inhibitors; side effects reduction; carriers; tablets; transdermal patches; Parkinson's disease; brain disorders; nervous system disorders; neurodegenerative disease; multiple sclerosis | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2010-07-29 | — | — | US | disclosed |
| US-20100190859-A1 | Monorasagiline citrate; salt formation; monoamine oxidase inhibitors; side effects reduction; carriers; tablets; transdermal patches; Parkinson's disease; brain disorders; nervous system disorders; neurodegenerative disease; multiple sclerosis | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2010-07-29 | — | — | US | disclosed |
| US-20100189791-A1 | Delayed release rasagiline malate formulation | TEVA PHARMACEUTICAL INDUSTRIES, LTD. | 2010-07-29 | — | — | US | disclosed |
| US-20100189791-A1 | Delayed release rasagiline malate formulation | TEVA PHARMACEUTICAL INDUSTRIES, LTD. | 2010-07-29 | — | — | US | disclosed |
| US-20100189790-A1 | Delayed release rasagiline formulation | TEVA PHARMACEUTICAL INDUSTRIES, LTD. | 2010-07-29 | — | — | US | disclosed |
| US-20100189788-A1 | Delayed release rasagiline base formulation | TEVA PHARMACEUTICAL INDUSTRIES, LTD. | 2010-07-29 | — | — | US | disclosed |
| US-20100189788-A1 | Delayed release rasagiline base formulation | TEVA PHARMACEUTICAL INDUSTRIES, LTD. | 2010-07-29 | — | — | US | disclosed |
| US-20090181086-A1 | Rasagiline formulations, their preparation and use | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2009-07-16 | — | — | US | disclosed |
| US-20090181086-A1 | Rasagiline formulations, their preparation and use | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230346733-A1 | ORAL FORMULATIONS OF BIPOLAR TRANS CAROTENOIDS | CRY1, CYP11B1, BBC3 | MMP8 4249/4885ACACB 1497/4885ACACA 1284/4885 |
| US-20100189790-A1 | Delayed release rasagiline formulation | RAB7A, RAB27A, RAB35 | MMP8 3054/4885ACACB 3969/4885ACACA 4051/4885 |
| US-20100190859-A1 | Monorasagiline citrate; salt formation; monoamine oxidase inhibitors; side effects reduction; carriers; tablets; transdermal patches; Parkinson's disease; brain disorders; nervous system disorders; neurodegenerative disease; multiple sclerosis | MAOA, PARK7, SLC18A2 | MMP8 2552/4885ACACB 1488/4885ACACA 951/4885 |
| US-11666538-B2 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof | COMT, MUC1, MLNR | MMP8 3922/4885ACACB 2811/4885ACACA 1848/4885 |
| US-20160354315-A1 | DOSAGE FORMS AND USE THEREOF | CYP2D6, CYP3A7, CYP3A5 | MMP8 4127/4885ACACB 2027/4885ACACA 1965/4885 |
| US-10016384-B2 | Oral formulations of bipolar trans carotenoids | CRY1, CYP11B1, BBC3 | MMP8 4249/4885ACACB 1497/4885ACACA 1284/4885 |
| US-20100189788-A1 | Delayed release rasagiline base formulation | RAB7A, RAB27A, RAB5B | MMP8 3345/4885ACACB 4078/4885ACACA 4130/4885 |
| US-20090181086-A1 | Rasagiline formulations, their preparation and use | RAB5B, RAB27A, RAB29 | MMP8 2710/4885ACACB 4231/4885ACACA 4253/4885 |
| US-20160296427-A1 | SYSTEM AND METHOD FOR APPLYING ORAL CARE AGENTS | OLA1, OTC, LPO | MMP8 22/4885ACACB 3091/4885ACACA 2119/4885 |
| US-20100189791-A1 | Delayed release rasagiline malate formulation | MDH1, MDH2, SLC25A11 | MMP8 2984/4885ACACB 1696/4885ACACA 1570/4885 |
| US-20180000903-A1 | Tablets Comprising GLP-1 Agonist and Enteric Coating | GLP1R, GIPR, SLC10A2 | MMP8 3903/4885ACACB 2950/4885ACACA 1285/4885 |
| US-20230301923-A1 | MUCO-ADHESIVE, CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOF | COMT, MLNR, MUC1 | MMP8 4423/4885ACACB 2562/4885ACACA 2392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.